Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

372 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Observational case-control study of the prevalence of chronic cerebrospinal venous insufficiency in multiple sclerosis: results from the CoSMo study.
Comi G, Battaglia MA, Bertolotto A, Del Sette M, Ghezzi A, Malferrari G, Salvetti M, Sormani MP, Tesio L, Stolz E, Zaratin P, Mancardi G; CoSMo Collaborative Study Group. Comi G, et al. Among authors: bertolotto a. Mult Scler. 2013 Oct;19(11):1508-17. doi: 10.1177/1352458513501231. Epub 2013 Sep 6. Mult Scler. 2013. PMID: 24014572 Free article.
Cognitive and psychosocial features of childhood and juvenile MS.
Amato MP, Goretti B, Ghezzi A, Lori S, Zipoli V, Portaccio E, Moiola L, Falautano M, De Caro MF, Lopez M, Patti F, Vecchio R, Pozzilli C, Bianchi V, Roscio M, Comi G, Trojano M; Multiple Sclerosis Study Group of the Italian Neurological Society. Amato MP, et al. Neurology. 2008 May 13;70(20):1891-7. doi: 10.1212/01.wnl.0000312276.23177.fa. Neurology. 2008. PMID: 18474844
Effect of laquinimod on MRI-monitored disease activity in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb study.
Comi G, Pulizzi A, Rovaris M, Abramsky O, Arbizu T, Boiko A, Gold R, Havrdova E, Komoly S, Selmaj K, Sharrack B, Filippi M; LAQ/5062 Study Group. Comi G, et al. Lancet. 2008 Jun 21;371(9630):2085-92. doi: 10.1016/S0140-6736(08)60918-6. Lancet. 2008. PMID: 18572078 Clinical Trial.
The brief neuropsychological battery for children: a screening tool for cognitive impairment in childhood and juvenile multiple sclerosis.
Portaccio E, Goretti B, Lori S, Zipoli V, Centorrino S, Ghezzi A, Patti F, Bianchi V, Comi G, Trojano M, Amato MP; Multiple Sclerosis Study Group of the Italian Neurological Society. Portaccio E, et al. Mult Scler. 2009 May;15(5):620-6. doi: 10.1177/1352458508101950. Epub 2009 Mar 24. Mult Scler. 2009. PMID: 19318511
Cognitive impairment and its relation with disease measures in mildly disabled patients with relapsing-remitting multiple sclerosis: baseline results from the Cognitive Impairment in Multiple Sclerosis (COGIMUS) study.
Patti F, Amato MP, Trojano M, Bastianello S, Tola MR, Goretti B, Caniatti L, Di Monte E, Ferrazza P, Brescia Morra V, Lo Fermo S, Picconi O, Luccichenti G; COGIMUS Study Group. Patti F, et al. Mult Scler. 2009 Jul;15(7):779-88. doi: 10.1177/1352458509105544. Mult Scler. 2009. PMID: 19542262
Effect of glatiramer acetate on conversion to clinically definite multiple sclerosis in patients with clinically isolated syndrome (PreCISe study): a randomised, double-blind, placebo-controlled trial.
Comi G, Martinelli V, Rodegher M, Moiola L, Bajenaru O, Carra A, Elovaara I, Fazekas F, Hartung HP, Hillert J, King J, Komoly S, Lubetzki C, Montalban X, Myhr KM, Ravnborg M, Rieckmann P, Wynn D, Young C, Filippi M; PreCISe study group. Comi G, et al. Lancet. 2009 Oct 31;374(9700):1503-11. doi: 10.1016/S0140-6736(09)61259-9. Epub 2009 Oct 6. Lancet. 2009. PMID: 19815268 Clinical Trial.
Effects of immunomodulatory treatment with subcutaneous interferon beta-1a on cognitive decline in mildly disabled patients with relapsing-remitting multiple sclerosis.
Patti F, Amato MP, Bastianello S, Caniatti L, Di Monte E, Ferrazza P, Goretti B, Gallo P, Morra VB, Lo Fermo S, Picconi O, Tola MR, Trojano M; COGIMUS Study Group. Patti F, et al. Mult Scler. 2010 Jan;16(1):68-77. doi: 10.1177/1352458509350309. Epub 2009 Dec 7. Mult Scler. 2010. PMID: 19995846 Clinical Trial.
Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis.
Cohen JA, Barkhof F, Comi G, Hartung HP, Khatri BO, Montalban X, Pelletier J, Capra R, Gallo P, Izquierdo G, Tiel-Wilck K, de Vera A, Jin J, Stites T, Wu S, Aradhye S, Kappos L; TRANSFORMS Study Group. Cohen JA, et al. N Engl J Med. 2010 Feb 4;362(5):402-15. doi: 10.1056/NEJMoa0907839. Epub 2010 Jan 20. N Engl J Med. 2010. PMID: 20089954 Free article. Clinical Trial.
Oral laquinimod in patients with relapsing-remitting multiple sclerosis: 36-week double-blind active extension of the multi-centre, randomized, double-blind, parallel-group placebo-controlled study.
Comi G, Abramsky O, Arbizu T, Boyko A, Gold R, Havrdová E, Komoly S, Selmaj K, Sharrack B, Filippi M; LAQ/5063 Study Group. Comi G, et al. Mult Scler. 2010 Nov;16(11):1360-6. doi: 10.1177/1352458510378127. Epub 2010 Sep 8. Mult Scler. 2010. PMID: 20834039 Clinical Trial.
Cognitive and psychosocial features in childhood and juvenile MS: two-year follow-up.
Amato MP, Goretti B, Ghezzi A, Lori S, Zipoli V, Moiola L, Falautano M, De Caro MF, Viterbo R, Patti F, Vecchio R, Pozzilli C, Bianchi V, Roscio M, Martinelli V, Comi G, Portaccio E, Trojano M; Multiple Sclerosis Study Group of the Italian Neurological Society. Amato MP, et al. Neurology. 2010 Sep 28;75(13):1134-40. doi: 10.1212/WNL.0b013e3181f4d821. Neurology. 2010. PMID: 20876467
372 results